The pharmaceutical industry is working to drum up support against proposals in Washington that threaten the current power structure of drug pricing in the U.S., according to a Wall Street Journal report.
Drugmakers, according to the report, are also losing their “political clout” as the public continues to express disapproval of rising drug prices.
Pfizer’s CFO, Frank D’Amelio, during a conference in August said wants to make the company’s firm position clear.
“We want to be proactive in terms of making sure our position is heard down in Washington,” he said. “And many of us, including myself, get down there and make sure we have the conversations that need to be had.”
To read the full report on WSJ, click here. (Paid subscription may be required)